Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Your medical records can be transferred to continue GLP-1 therapy with another provider
Semaglutide is a GLP-1 receptor agonist that, for many patients, provides sufficient appetite control and weight loss support without needing the dual-agonist approach that tirzepatide offers
It is likely that the majority of these effects is explained by the massive weight loss
Other safety considerations include: Injection site reactions : redness, itching, or lumps may occur with subcutaneous formulations Gallbladder disease : increased risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) has been reported Diabetic retinopathy : rapid improvement in glycaemic control may temporarily worsen retinopathy in susceptible individuals, particularly those with pre-existing retinopathy who are also using insulin
Wischmeyer, 2003
Clinical Trial Outcomes with Monotherapy The REDEFINE 1 trial demonstrated that cagrilintide monotherapy at the 4.5 mg maintenance dose produced mean body weight reductions of approximately 10.8% from baseline after 32 weeks of treatment [4]
